Erratum: Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers (Clin. Pharmacol. Ther. (2010) 87 (601608) (doi:10.1038/clpt.2010.20));Pharmacokinetic/Pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 5, 2010, Pages 601-608

  Lindauer, A ^a   Di Gion, P ^b   Kanefendt, F ^a   Tomalik Scharte, D ^b   Kinzig, M ^c   Rodamer, M ^c   Dodos, F ^b   Sorgel F ^c   Fuhr, U ^b   Jaehde, U ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; DRUG METABOLITE; PROTEIN; SU 12662; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MODEL; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; SIMULATION; SYSTOLIC BLOOD PRESSURE; VOLUNTEER;

EID: 77951499421     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.115     Document Type: Erratum

References (36)

1. Rini, B.I. Sunitinib. Expert Opin. Pharmacother. 8, 2359-2369 (2007)
2. Teicher, B.a. & Ellis, L.M. (eds.). antiangiogenic agents in Cancer Therapy 2nd edn. (Humana Press, Totowa, NJ, 2008).
3. Jain, R.K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009).
4. Jubb, a.M., Oates, a.J., Holden, S. & Koeppen, H. Predicting beneft from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 6, 626-635 (2006).
5. Ebos, J.M., Lee, C.R., Christensen, J.G., Mutsaers, a.J. & Kerbel, R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efcacy. Proc. Natl. Acad. Sci. U.S.A. 104, 17069-17074 (2007)
6. azizi, M., Chedid, a. & Oudard, S. Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med. 358, 95-97 (2008).
7. Burstein, H.J. et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26, 1810-1816 (2008).
8. Deprimo, S.E. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 5, 32 (2007).
9. Kontovinis, L.F., Papazisis, K.T., Touplikioti, P., andreadis, C., Mouratidou, D. & Kortsaris, a.H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9, 82 (2009).
10. Norden-Zfoni a. et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 13. 2643-2650 (2007).
11. Rixe, O., Billemont, B. & Izzedine, H. Hypertension as a predictive factor of Sunitinib activity. Ann. Oncol. 18, 1117 (2007).
12. Motzer, R.J. et al. activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
13. George, S. et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer 45, 1959-1968 (2009).
14. Hempel, G., Karlsson, M.O., de alwis, D.P., Toublanc, N., McNay, J. & Schaefer, H.G. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin. Pharmacol. Ther. 64, 622-635 (1998).
15. Evans, N.D., Godfrey, K.R., Chapman, M.J., Chappell, M.J., aarons, L. & Dufull, S.B. an identifability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J. Pharmacokinet. Pharmacodyn. 28, 93-105 (2001).
16. Webb, J.a., Rostami-Hodjegan, a., abdul-Manap, R., Hofmann, U., Mikus, G. & Kamali, F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br. J. Clin. Pharmacol. 52, 35-43 (2001).
17. Johnson, T.N., Rostami-Hodjegan, a., Goddard, J.M., Tanner, M.S. & Tucker, G.T. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br. J. Anaesth. 89, 428-437 (2002).
18. Bello, C.L. et al. Efect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer. Drugs 17, 353-358 (2006).
19. Danhof, M., de Jongh, J., De Lange, E.C., Della Pasqua, O., Ploeger, B.a. & Voskuyl, R.a. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357-400 (2007).
20. Mendel, D.B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
21. Horowitz, J.R. et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 17, 2793-2800 (1997).
22. Mourad, J.J., des Guetz, G., Debbabi, H. & Levy, B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. a crucial role for microcirculation. Ann. Oncol. 19, 927-934 (2008)
23. Coca, a. Circadian rhythm and blood pressure control: physiological and pathophysiological factors. J. Hypertens. Suppl. 12, S13-S21 (1994).
24. Ravaud, a. & Sire, M. arterial hypertension and clinical beneft of sunitinib, sorafenib and bevacizumab in frst and second-line treatment of metastatic renal cell cancer. Ann. Oncol. 20, 966-7; author reply 967 (2009).
25. Rini, B.I. et al. association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (aG-013736). J. Clin. Oncol. (Meeting abstracts) 2008, abstr 3543.
26. Eppler, S.M. et al. a target-mediated model to describe the pharmacokinetics and hemodynamic efects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 72, 20-32 (2002).
27. Kranz, A., Mattfeldt, T. & Waltenberger, J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int. J. Cancer 84, 293-298 (1999).
28. Elsinghorst, P.W. & Gutschow, M. Synthesis of H-2-and C-13-labelled sunitinib and its primary metabolite. J. Labelled Comp. Rad. 52, 360-365 (2009).
29. Beal, S.L., Sheiner, L.B. & Boeckmann, a.J. (eds.) NONMEM Users Guide (1989-2006) (Icon Development Solutions, Ellicott City, MD, 2006).
30. Houk, B.E., Bello, C.L., Kang, D. & amantea, M. a population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15, 2497-2506 (2009).
31. Savic, R.M., Jonker, D.M., Kerbusch, T. & Karlsson, M.O. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34, 711-726 (2007).
32. Faivre, S., Demetri, G., Sargent, W. & Raymond, E. Molecular basis for sunitinib efcacy and future clinical development. Nat. Rev. Drug Discov. 6, 734-745 (2007).
33. Izzedine, H. et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann. Oncol. 20, 807-815 (2009).
34. Mager, D.E. & Jusko, W.J. Pharmacodynamic modeling of time-dependent transduction systems. Clin. Pharmacol. Ther. 70, 210-216 (2001).
35. Dayneka, N.L., Garg, V. & Jusko, W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21, 457-478 (1993).
36. Lindbom, L., Pihlgren, P., Jonsson, E.N. & Jonsson, N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed efect modeling using NONMEM. Comput. Methods Programs Biomed. 79, 241-257 (2005).